Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from CStone Pharmaceuticals ( (HK:2616) ) is now available.
CStone Pharmaceuticals has appointed Mr. Kenneth Howard Jarrett as an independent non-executive director, effective September 23, 2025. Mr. Jarrett brings over 40 years of experience in government and business relations, strategic planning, and key relationship building, having held significant positions in U.S. consulates and private sector organizations. His appointment is expected to strengthen CStone’s strategic and audit committees, potentially enhancing the company’s governance and strategic direction. This move may positively impact CStone’s standing in the biopharmaceutical industry, offering stakeholders confidence in its leadership and future growth prospects.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative immuno-oncology therapies and precision medicines. The company is listed on the Hong Kong Stock Exchange and is dedicated to addressing unmet medical needs in the oncology sector.
Average Trading Volume: 22,971,684
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.28B
For an in-depth examination of 2616 stock, go to TipRanks’ Overview page.